Otis Clapp & Son, Inc. v. Filmore Vitamin Company D/B/A Medique Products

754 F.2d 738, 225 U.S.P.Q. (BNA) 387, 1985 U.S. App. LEXIS 28979
Court of Appeals for the Seventh Circuit·Decided February 4, 1985·No. 83-2931·Published·Cited by 151 cases

Opinion

COFFEY, Circuit Judge.

The plaintiff appeals not only the amount it recovered in an unfair trade competition action but also the denial of motions to supplement its complaint and to compel discovery. We affirm.

I.

Both the plaintiff, Otis Clapp & Son, Inc. (“Otis Clapp”) and the defendant, Medique Products (“Medique”), a division of the Filmore Vitamin Company, sell non-prescription pharmaceuticals in the institutional medical market. Both companies sell their pharmaceutical supplies through distributors to the end-purchasers who, typically are nurses employed in plant or office clinics. Medique entered the market in 1975 or 1976 and developed a line of pharmaceuticals that competed against many of Otis Clapp’s products. At that time, Otis Clapp was an established and growing business.

Otis Clapp complained of five unfair trade practices by Medique: (1) infringement of several of its trademarks; (2) false, misleading, and deceptive comparative advertising; (3) false statements about the quality and effectiveness of Otis Clapp products and their ingredients; (4) false representations that certain Otis Clapp products did not conform to Food and Drug Administration Guidelines; and (5) the hiring of James Rose, a former Otis Clapp employee, in order that they might obtain confidential information from him. 1 Specifically, Otis Clapp asserted that FEMAIDS, Medique’s menstrual relief medication, infringed Otis Clapp’s trademark for FEM-CAPS, also a menstrual relief medication. Furthermore, Otis Clapp objected to Medique’s use of the name DISPENSER-PAK for its individual dose dispensing packaging as an infringement of Otis Clapp’s DIS-PENS-A-KIT trademark, used by Otis Clapp to describe similar packaging. The comparative advertising and false statement claims were based on a 1977 Medique brochure, which was used both as a sales promotion device and to interest new distributors in handling the Medique line. In addition, the literature was also given to existing Medique distributors to be disseminated to final purchasers.

Otis Clapp filed its complaint in 1978 alleging claims under Section 35 of the Lanham Act (“Act”), 15 U.S.C. § 1117, as well as state law claims for trademark infringement. 2 On January 22,1982, the district court granted a partial summary judgment to Otis Clapp, enjoining Medique from disseminating some of its literature and making representations that Otis Clapp’s cough and cold products do not conform with the guidelines of the FDA review panel for cough and cold products. Medique was also enjoined from claiming that certain Otis Clapp products did not contain an effective dosage of salicylamide.

On October 22, 1982, the defendant admitted liability under the Lanham Act and state law claims without conceding damages. The defendant’s counsel informed the court that his client was without funds, could not afford to pay attorney’s fees, and could not afford to respond to the plaintiff’s discovery program. According to the representations made to the district court, the defendant admitted liability solely because it was financially unable to litigate the issue. Attempting to avoid both a damages hearing and supplemental proceedings under Fed.R.Civ.P. 69, the district court encouraged the parties to negotiate a settlement as to the amount of damages.

During monthly status hearings held from November 22, 1982 through February 15, 1983, the parties presented several of *741 their points of contention to the district court. The plaintiff, concerned about whether Medique had transferred its assets to another corporation, questioned whether or not it was receiving an accurate depiction of the defendant’s resources or was being misled as to its ability to respond in damages. The plaintiff pointed out that in 1979, Filmore Vitamin changed its corporate name to I. Udell Associates, Inc. and transferred its packaging operations, including inventory and equipment, to a newly formed affiliate company named Filmore Vitamin, Inc. The defendant objected to the plaintiff’s attempt to inquire into the defendant’s assets, properly asserting that the plaintiff could discover the defendant’s assets in a supplemental proceeding under Rule 69. Furthermore, the defendant repeatedly complained to the court that the plaintiff had failed to submit settlement proposals and protested that the plaintiff in fact was prolonging the litigation in order that it might force the defendant out of business. The plaintiff on frequent occasions requested the district court to schedule a trial date on the damage issues. The district court attempted to strike a balance between protecting the defendant from oppressive discovery and, on the other hand, allowing the plaintiff the opportunity to obtain sufficient information about the defendant’s financial status to make an informed evaluation of the settlement offer. The plaintiff was allowed to depose Irving Udell, the principal figure of I. Udell & Associates, Inc. In addition, the defendant supplied the plaintiff with corporate documents and financial reports, and an opinion letter from a disinterested attorney who examined the financial data and concluded that Medique’s corporate assets had not been siphoned off. The settlement negotiations fell apart in February 1983 when the plaintiff demanded $192,000 in settlement before the damages trial. After the failure of the settlement negotiations, the defendant filed a motion for attorney’s fees pursuant to 28 U.S.C. § 1927 arguing that the plaintiff had deliberately protracted the litigation.

Free access — add to your briefcase to read the full text and ask questions with AI

Otis Clapp & Son, Inc. v. Filmore Vitamin Company D/B/A Medique Products, 754 F.2d 738, 225 U.S.P.Q. (BNA) 387, 1985 U.S. App. LEXIS 28979 (7th Cir. 1985).

754 F.2d 738 (Otis Clapp & Son, Inc. v. Filmore Vitamin Company D/B/A Medique Products) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Carson v. Emergency MD LLC
D. South Carolina, 2025
Fabick, Inc. v. Fabco Equip., Inc.
296 F. Supp. 3d 1022 (W.D. Wisconsin, 2017)
Jay Vermillion v. Mark Levenhagen
604 F. App'x 508 (Seventh Circuit, 2015)
City of Milwaukee v. Andrew Spengler
573 F. App'x 601 (Seventh Circuit, 2014)
['GUTTENBERG v. EMERY']
26 F. Supp. 3d 88 (District of Columbia, 2014)
Binder v. DISABILITY GROUP, INC.
772 F. Supp. 2d 1172 (C.D. California, 2011)
Rainbow Play Systems, Inc. v. Groundscape Technologies, LLC
364 F. Supp. 2d 1026 (D. Minnesota, 2005)
West v. MacHt
235 F. Supp. 2d 966 (E.D. Wisconsin, 2002)
Allergy Asthma Technology, Ltd. v. I Can Breathe, Inc.
195 F. Supp. 2d 1059 (N.D. Illinois, 2002)
PBM Products, Inc. v. Mead Johnson & Co.
174 F. Supp. 2d 424 (E.D. Virginia, 2001)
Finance Investment Co. (Bermuda) Ltd. v. Geberit Ag
165 F.3d 526 (Seventh Circuit, 1998)
Four Star Capital Corp. v. Nynex Corp.
183 F.R.D. 91 (S.D. New York, 1997)